E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
The urea cycle disorders are inborn errors of metabolism that affect the transfer of nitrogen into urea. There are seven disorders to be investigated: carbamoylphosphate synthetase I deficiency [CPS ID], ornithine transcarbamylase deficiency [OTCD], argininosuccinic acid synthetase deficiency [ASSD], argininosuccinic acid lyase deficiency [ASLD], arginase deficiency [ARGD], N-acetylglutamate synthase deficiency [NAGSD], and citrine deficiency. |
|
E.1.1.1 | Medical condition in easily understood language |
metabolic disease of the urea cycle in the liver that result in failed detoxification of ammonia. |
Trouble du métabolisme du cycle de l'urée résultant en l'absence partielle ou totale de la détoxification de l'ammoniac. |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Nutritional and Metabolic Diseases [C18] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 18.0 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10013373 |
E.1.2 | Term | Disorders of urea cycle metabolism |
E.1.2 | System Organ Class | 100000004861 |
|
E.1.3 | Condition being studied is a rare disease | Yes |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To asses the efficacy during the year following HepaStem infusions (functional parameters). |
Evaluation de l'efficacité d'HepaStem au cours de l'année qui suit les infusions (paramètres fonctionnels). |
|
E.2.2 | Secondary objectives of the trial |
1. To assess the efficacy during the year following HepaStem infusions (biological and clinical parameters)
2. To evaluate the safety during the year following HepaStem infusions. |
1. Evaluation de l'efficacité d'HepaStem au cours de l'année qui suit les infusions (paramètres biologiques et cliniques).
2. Evaluation de l'efficacité d'HepaStem au cours de l'année qui suit les infusions |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1. The patient is a pediatric patient.
2. The patient presents with one of the following UCDs (carbamoylphosphate synthetase I [CPS I] deficiency [CPS ID], ornithine transcarbamylase [OTC] deficiency [OTCD], argininosuccinic acid synthetase [ASS] deficiency [ASSD], argininosuccinic acid lyase [ASL] deficiency [ASLD], arginase [ARG] deficiency [ARGD], N-acetylglutamate synthase [NAGS] deficiency [NAGSD]) and citrine deficiency of such severity that liver transplantation or alternatives are warranted despite full conservative therapy, and/or experiences serious impairment in quality of life (QoL) despite full conservative therapy.
3. The patient shows patency of the portal vein and branches, with normal flow velocity in the main portal vein as confirmed by Doppler US and accessibility of the portal vein and /or affluants, or of the umbilical vein.
4. Female subjects of childbearing potential need to have a negative pregnancy test and must agree to use an acceptable method of contraception throughout the study.
5. The patient (if capable of signing) and parents or legal representative have signed a written informed assent/consent form.
|
|
E.4 | Principal exclusion criteria |
1. The patient has mild disease severity, easily controlled under standard of care therapy, with no recurrent metabolic crises.
2. The patient is registered on a liver transplant waiting list or is scheduled for living donor liver transplantation before the end of the study.
3. The patient presents acute liver failure.
4. The patient presents clinical or radiological evidence of liver cirrhosis.
5. The patient presents or has a history of hepatic or extrahepatic malignancy.
6. The patient has a known clinically significant cardiac malformation.
7. The patient has a personal history of venous thrombosis. In case of known family history, a complete coagulation work-up should be performed, and results need to be discussed with PB before enrolling the patient in the study.
8. The patient participates currently in another clinical trial – except disease registry and observational HepaStem study.
9. The patient underwent previous mature liver cell or stem cell transplantation or received an organ liver transplant or received HepaStem infusion.
10. The patient has a contraindication to solumedrol, tacrolimus.
11. The patient has a known hypersensitivity or allergy to bivalirudin.
12. The patient has a known hypersensitivity or allergy to the antibiotics preventing post-operative infections that are prescribed according to institutional guidelines, and no alternative prophylaxis can be found.
13. The patient had or has a renal insufficiency treated by dialysis.
14. The patient requires valproate therapy.
15. The patient has a known hypersensitivity or allergy to contrast agents (if applicable) that cannot be treated adequately.
16. The patient has a thrombosis of the portal vein or persisting impairment of anterograde portal blood flow.
17. The patient has a porto systemic shunt or fistula assessed by Doppler US.
18. For permanent catheter: the prospective placement site has previously suffered from venous thrombosis or vascular surgical procedures.
19. For umbilical vein access: the patient has any contraindication for umbilical vein catheterization (e.g. history of peritonitis, necrotizing enterocolitis, etc).
20. The patient has an ongoing infection or suffered from an infection in the last 2 weeks.
21. There is any significant condition that, in the Investigator’s opinion, may interfere with the patient’s optimal participation in the study.
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
The primary endpoint will be the change in urea formation during the year following HepaStem infusions. A 13C tracer method will be used to measure ureagenesis (fasten condition). |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
13C tracer method to measure ureagenesis (fasting condition) measured at baseline, 3m, 6m, 9m, and 12m follow-up. |
|
E.5.2 | Secondary end point(s) |
1. Efficacy up to 12 months post-first infusion day for each individual patient and for all patients as compared to his/her prior medical condition based on:
- Ammonia (NH3) values (fasting condition)
- Full aminoacidogram in plasma (fasting condition)
- Evaluation of UCD condition (report of metabolic decompensations, report on actual supportive treatment and adjustment of protein restriction [low protein diet], amino acids supplements, report on behavior, cognitive skills and health-related QoL indicators).
Exploratory: engraftment capacity of HepaStem in the liver of all patients 2 months post-first infusion day by establishing donor sequences by real time polymerase chain reaction (RT-PCR) or fluorescence in situ hybridization (FISH) or immunohistochemistry on biopsies.
2. Safety during the year following HepaStem infusions in terms of:
- Clinical status (physical examination and vital signs)
- Portal-vein hemodynamics
- Morphology of the liver, bile ducts and portal system
- Laboratory tests
- De novo detection of donor-specific circulating anti-human leukocyte antigen (HLA) antibodies, and/or other immune-related markers
- Serious Adverse Events (SAEs) and clinically significant Adverse Events (AEs) related to HepaStem (infusion and follow-up), technical intervention, and concomitant treatments. |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
Efficacy periods:
- Active Treatment
- Follow-up.
The safety parameters will be assessed for 5 time windows:
1) Screening Period
- Time window 1 = first visit - end of Screening Period.
2) Active Treatment Period
- Time window 2 (inpatient period) = D0 - Ddischarge.
- Time window 3 = Ddischarge - next infusion day or end of Active Treatment Period.
3) Follow-up Period
- Time window 4 (outpatient period) = Visit (V)3 months post-first infusion day - V12 months post-first infusion day.
- Time window 5 = screening - V12 months post-first infusion day. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 11 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | |
E.8.9.1 | In the Member State concerned months | 32 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial months | 32 |
E.8.9.2 | In all countries concerned by the trial days | 0 |